Caffeine-inducible gene switches controlling experimental diabetes

Area of Science:

• Synthetic biology
• Biotechnology
• Genetic engineering

Background:

• Controlling transgene expression remotely and without side effects is crucial for cell-based therapies.
• Existing trigger-inducible gene expression systems face limitations in achieving precise, side-effect-free control.

Purpose of the Study:

• To establish a novel caffeine-inducible protein dimerization system for precise transgene control.
• To demonstrate the system's efficacy in regulating gene expression in response to physiological caffeine concentrations.
• To evaluate the therapeutic potential of this system in a type-2 diabetes mouse model.

Main Methods:

• Development of a caffeine-binding single-domain antibody-based protein dimerization system.
• Engineering synthetic transcription factors and cell-surface receptors responsive to caffeine.
• Utilizing the caffeine-stimulated advanced regulators (C-STAR) system for dose-dependent and reversible transgene control.
• Implanting microencapsulated C-STAR-equipped cells in type-2 diabetic mice for glucagon-like peptide 1 expression.

Main Results:

• The C-STAR system enabled caffeine-inducible transgene expression at physiologically relevant concentrations.
• Coffee consumption dose-dependently and reversibly controlled transgene expression in designer cells.
• Type-2 diabetic mice treated with C-STAR cells showed improved glucose homeostasis after coffee intake.
• Caffeine demonstrated non-toxic, inexpensive, and beverage-specific control over biopharmaceutical production.

Conclusions:

• The C-STAR system offers a novel, side-effect-free method for remote control of transgene expression.
• This system has significant potential for cell-based therapies and biopharmaceutical production by integrating with lifestyle.
• Caffeine-inducible gene regulation represents a promising advancement in synthetic biology for therapeutic applications.